Noclonal antibodies (nimotuzumab). 12 supported the use of bevacizumab. In absence of
Noclonal antibodies (nimotuzumab). 12 supported the usage of bevacizumab. In absence of a molecular genetic profile for the initial case scenario, 81 of respondents stated that they would pick out…